Top

Drugs in R&D

Published in:

Open Access 01-09-2011 | Review Article

Impact of Respiratory Syncytial Virus

The Nurse’s Perspective

Authors: Marianne Bracht, RN, Debbie Basevitz, Marilyn Cranis, Rose Paulley

Published in: Drugs in R&D | Issue 3/2011

Abstract

Respiratory syncytial virus (RSV) is a highly contagious virus, and is the major cause of lower respiratory tract infections in infants and toddlers worldwide.RSV infection poses serious health risks to young children during the first 2 years of life. Several infant populations have been classified as high risk, and additional risk factors are known to increase the likelihood of severe RSV infection. Treatment for active RSV infection is limited to the symptoms of infection rather than the underlying cause; therefore, it is critical to reduce the transmission of RSV. As nurses, we highlight the importance of educating healthcare professionals, both in the hospital and community settings, aswell as parents and other caregivers about the risks and outcomes associated with RSV infection, and necessarymeasures to decrease the risk of infection. We also highlight the importance of the successful identification of those children who are at high risk of RSV infection. RSV prophylaxis (RSVP) with palivizumab has been shown to improve clinical outcome in infants who are considered high risk compared with those who have not received RSVP. The failure of healthcare staff and primary caregivers to protect children against an RSV infection can have lasting detrimental effects on the health and lives of affected children and their families.

Morris JA, Blount Jr RE, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med 1956 Jul; 92 (3): 544–9PubMed

Mufson MA, Belshe RB, Orvell C, et al. Respiratory syncytial virus epidemics: variable dominance of subgroups A and B strains among children, 1981–1986. J Infect Dis 1988 Jan; 157 (1): 143–8PubMedCrossRef

Waris M. Pattern of respiratory syncytial virus epidemics in Finland: two-year cycles with alternating prevalence of groups A and B. J Infect Dis 1991 Mar; 163 (3): 464–9PubMedCrossRef

Gilca R, De Serres G, Tremblay M, et al. Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons. J Infect Dis 2006 Jan 1; 193 (1): 54–8PubMedCrossRef

Henderson FW, Collier AM, Clyde Jr WA, et al. Respiratory- syncytial-virus infections, reinfections and immunity: a prospective, longitudinal study in young children. N Engl J Med 1979 Mar 8; 300 (10): 530–4PubMedCrossRef

Simoes EA. Respiratory syncytial virus infection. Lancet 1999 Sep 4; 354 (9181): 847–52PubMedCrossRef

Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986 Jun; 140 (6): 543–6PubMed

Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001 Jun 21; 344 (25): 1917–28PubMedCrossRef

Blydt-Hansen T, Subbarao K, Quennec P, et al. Recovery of respiratory syncytial virus from stethoscopes by conventional viral culture and polymerase chain reaction. Pediatr Infect Dis J 1999 Feb; 18 (2): 164–5PubMedCrossRef

10.

Bracht M, Heffer M, O’Brien K. Development, implementation, and evaluation of a community- and hospital-based respiratory syncytial virus prophylaxis program. Adv Neonatal Care 2005 Feb; 5 (1): 39–49PubMedCrossRef

11.

Hall CB, Douglas Jr RG, Geiman JM. Possible transmission by fomites of respiratory syncytial virus. J Infect Dis 1980 Jan; 141 (1): 98–102PubMedCrossRef

12.

Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003 Jan 8; 289 (2): 179–86PubMedCrossRef

13.

Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003 Nov; 143 (5 Suppl.): S150–6PubMed

14.

Schanzer DL, Langley JM, Tam TW. Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr Infect Dis J 2006 Sep; 25 (9): 795–800PubMedCrossRef

15.

Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial virus infection: a systematic review. Crit Care 2006; 10 (4): R107PubMedCrossRef

16.

Kneyber MCJ, Brandenburg AH, de Groot R, et al. Risk factors for respiratory syncytial virus associated apnoea. Eur J Pediatr 1998; 157 (4): 331–5PubMedCrossRef

17.

Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999 Aug 14; 354 (9178): 541–5PubMedCrossRef

18.

Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005 Jan 15; 171 (2): 137–41PubMedCrossRef

19.

Hislop AA, Hawarth SG. Airway size and structure in the normal fetal and infant lung and the effect of premature delivery and artificial ventilation. Am Rev Respir Dis 1989; 140: 1717–2PubMedCrossRef

20.

Yeung CY, Hobbs JR. Serum-gamma-G-globulin levels in normal premature, post-mature, and “small-for-dates” newborn babies. Lancet 1968 Jun 1; I (7553): 1167–70CrossRef

21.

Coffman S. Late preterm infants and risk for RSV. MCN Am J Matern Child Nurs 2009 Nov–Dec; 34 (6): 378–84PubMedCrossRef

22.

Engle WA, Tomashek KM, Wallman C. “Late-preterm” infants: a population at risk. Pediatrics 2007 Dec; 120 (6): 1390–401PubMedCrossRef

23.

Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 2003 Nov; 143 (5 Suppl.): S127–32PubMed

24.

Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010 May 1; 375 (9725): 1545–55PubMedCrossRef

25.

Welliver RC, Checchia PA, Bauman JH, et al. Fatality rates in published reports of RSV hospitalizations among highrisk and otherwise healthy children. Curr Med Res Opin 2010 Sep; 26 (9): 2175–81PubMedCrossRef

26.

Armstrong D, Grimwood K, Carlin JB, et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol 1998 Dec; 26 (6): 371–9PubMedCrossRef

27.

Arnold SR, Wang EE, Law BJ, et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J 1999 Oct; 18 (10): 866–9PubMedCrossRef

28.

Bloemers BL, van Furth AM, Weijerman ME, et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis — a prospective birth-cohort study. Pediatrics 2007 Oct; 120 (4): e1076–81PubMedCrossRef

29.

Resch B, Manzoni P, Lanari M. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Respir Rev 2009 Sep; 10 (3): 148–53PubMedCrossRef

30.

Martinez FD, Morgan WJ, Wright AL, et al. Diminished lung function as a predisposing factor for wheezing respiratory illness in infants. N Engl J Med 1988 Oct 27; 319 (17): 1112–7PubMedCrossRef

31.

Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995 Feb; 126 (2): 212–9PubMedCrossRef

32.

Synagis® [package insert]. Gaithersburg (MD): MedImmune, LLC, 2010

33.

Cilla G, Sarasua A, Montes M, et al. Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain. Epidemiol Infect 2006 Jun; 134 (3): 506–13PubMedCrossRef

34.

Carbonell-Estrany X, Quero J. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001 Sep; 20 (9): 874–9PubMedCrossRef

35.

Figueras-Aloy J, Carbonell-Estrany X, Quero J. Casecontrol study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain. Pediatr Infect Dis J 2004 Sep; 23 (9): 815–20PubMedCrossRef

36.

Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004 Sep; 23 (9): 806–14PubMedCrossRef

37.

Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003 Nov; 143 (5 Suppl.): S118–26PubMed

38.

Anderson LJ, Parker RA, Strikas RA, et al. Day-care center attendance and hospitalization for lower respiratory tract illness. Pediatrics 1988 Sep; 82 (3): 300–8PubMed

39.

Carbonell-Estrany X, Figueras-Aloy J, Law BJ. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J 2004 Nov; 23 (11 Suppl.): S193–201PubMed

40.

Holberg CJ, Wright AL, Martinez FD, et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol 1991 Jun 1; 133 (11): 1135–51PubMed

41.

Bradley JP, Bacharier LB, Bonfiglio J, et al. Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy. Pediatrics 2005 Jan; 115 (1): e7–14PubMed

42.

Groskreutz DJ, Monick MM, Babor EC, et al. Cigarette smoke alters respiratory syncytial virus-induced apoptosis and replication. Am J Respir Cell Mol Biol 2009 Aug; 41 (2): 189–98PubMedCrossRef

43.

Samson L. Prevention of respiratory syncytial virus infection. Paediatr Child Health 2009 Oct; 14 (8): 521–32PubMed

44.

Sampalis JS, Langley J, Carbonell-Estrany X, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008 Jul–Aug; 28 (4): 471–80PubMedCrossRef

45.

Dowell SF, Anderson LJ, Gary Jr HE, et al. Respiratory syncytial virus is an important cause of communityacquired lower respiratory infection among hospitalized adults. J Infect Dis 1996 Sep; 174 (3): 456–62PubMedCrossRef

46.

Boyce JM, Pittet D. Guideline for Hand Hygiene in Health- Care Settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol 2002 12/01; 23 (S12): S3–40PubMedCrossRef

47.

Hall CB. Nosocomial respiratory syncytial virus infections: the “Cold War” has not ended. Clin Infect Dis 2000 Aug; 31 (2): 590–6PubMedCrossRef

48.

Langley JM, LeBlanc JC, Wang EE, et al. Nosocomial respiratory syncytial virus infection in Canadian pediatric hospitals: a Pediatric Investigators Collaborative Network on Infections in Canada Study. Pediatrics 1997 Dec; 100 (6): 943–6PubMedCrossRef

49.

Groothuis J, Bauman J, Malinoski F, et al. Strategies for prevention of RSV nosocomial infection. J Perinatol 2008 May; 28 (5): 319–23PubMedCrossRef

50.

Isaacs D, Dickson H, O’Callaghan C, et al. Handwashing and cohorting in prevention of hospital acquired infections with respiratory syncytial virus. Arch Dis Child 1991 Feb; 66 (2): 227–31PubMedCrossRef

51.

Schiller O, Levy I, Pollak U, et al. Central apnoeas in infants with bronchiolitis admitted to the paediatric intensive care unit. Acta Paediatr 2010 Feb; 100 (2): 216–9PubMedCrossRef

52.

Paes BA, Mitchell I, Banerji A, et al. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. Can Respir J 2011 Mar–Apr; 18 (2): e10–9PubMed

53.

Mitchell I. Treatment of RSV bronchiolitis: drugs, antibiotics. Paediatr Respir Rev 2009 Jun; 10 Suppl. 1: 14–5PubMedCrossRef

54.

Zorc JJ, Hall CB. Bronchiolitis: recent evidence on diagnosis and management. Pediatrics 2010 Feb; 125 (2): 342–9PubMedCrossRef

55.

Law BJ, Wang EE, MacDonald N, et al. Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database. Pediatrics 1997 Mar; 99 (3): E7PubMedCrossRef

56.

Zhu Q, McAuliffe JM, Patel NK, et al. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J Infect. Dis 2011 Mar; 203: 674–82PubMedCrossRef

57.

Feltes TF, Sondheimer HM, Tulloh RMR, et al. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res 2011 Aug; 70 (2): 186–91PubMedCrossRef

58.

Group TI-RS. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics 1998 Sep; 102 (3): 531–7CrossRef

59.

Grimaldi M, Gouyon B, Sagot P, et al. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia. Pediatr Pulmonol 2007 Mar; 42 (3): 189–92PubMedCrossRef

60.

Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, et al. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 2003 Sep; 22 (9): 823–7PubMedCrossRef

61.

Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003 Oct; 143 (4): 532–40PubMedCrossRef

62.

Empey KM, Peebles Jr RS, Kolls JK. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis 2010 May 1; 50 (9): 1258–67PubMedCrossRef

63.

Orr P, McDonald S, Milley D, et al. Bronchiolitis in Inuit children from a Canadian central arctic community, 1995–1996. Int J Circumpolar Health 2001 Nov; 60 (4): 649–58PubMed

64.

National Advisory Committee on Immunization. Canadian Immunization Guide. 7th ed. Ottawa (ON): Publishing and Depository Services, Public Works and Government Services Canada, 2006

65.

Wu SY, Bonaparte J, Pyati S. Palivizumab use in very premature infants in the neonatal intensive care unit. Pediatrics 2004 Nov; 114 (5): e554–6PubMedCrossRef

66.

Simoes EA, Carbonell-Estrany X, Rieger CH, et al. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol 2010 Aug; 126 (2): 256–62PubMedCrossRef

67.

Boyce TG, Mellen BG, Mitchel Jr EF, et al. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000 Dec; 137 (6): 865–70PubMedCrossRef

68.

Elhassan NO, Sorbero ME, Hall CB, et al. Costeffectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006 Oct; 160 (10): 1070–6PubMedCrossRef

69.

Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007; 25 (1): 55–71PubMedCrossRef

70.

Reeve CA, Whitehall JS, Buettner PG, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J Paediatr Child Health 2006 May; 42 (5): 253–8PubMedCrossRef

71.

Lanctôt KL, Masoud ST, Paes BA, et al. The costeffectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis. Curr Med Res Opin 2008 Nov; 24 (11): 3223–37PubMedCrossRef

72.

Paes B, Steele S, Janes M, et al. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks’ gestational age in Canada. Curr Med Res Opin 2009 Jul; 25 (7): 1585–91PubMedCrossRef

73.

Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev 1998 Jul; 11 (3): 430–9PubMed

74.

Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969 Apr; 89 (4): 422–34PubMed

75.

Chang J. Current progress on development of respiratory syncytial virus vaccine. BMB Reports 2011 Apr; 44 (4): 232–7PubMedCrossRef

Title: Impact of Respiratory Syncytial Virus
The Nurse’s Perspective
Authors: Marianne Bracht, RN
Debbie Basevitz
Marilyn Cranis
Rose Paulley
Publication date: 01-09-2011
Publisher: Springer International Publishing
Published in: Drugs in R&D / Issue 3/2011
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI: https://doi.org/10.2165/11593140-000000000-00000

2024 ASCO Annual Meeting

Springer Medicine

Impact of Respiratory Syncytial Virus

The Nurse’s Perspective

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Impact of Intravenous Naltrexone on Intravenous Morphine-Induced High, Drug Liking, and Euphoric Effects in Experienced, Nondependent Male Opioid Users

Clinical and Experimental Applications of Sodium Phenylbutyrate

Short-Term Acetylsalicylic Acid (Aspirin) Use for Pain, Fever, or Colds —Gastrointestinal Adverse Effects

Seated Cuff Blood Pressure-Lowering Efficacy of an Olmesartan Medoxomil-Based Treatment Regimen in Patients with Type 2 Diabetes Mellitus